These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 19450200)

  • 1. Lipid treatment guidelines and cardiovascular risk for Aboriginal people in Central Australia.
    Luke JN; Brown A; O'Neal DN; O'Dea K; Jenkins AJ; Kelaher M; Best JD; Rowley KG
    Med J Aust; 2009 May; 190(10):552-6. PubMed ID: 19450200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absolute cardiovascular disease risk and lipid-lowering therapy among Aboriginal and Torres Strait Islander Australians.
    Calabria B; Korda RJ; Lovett RW; Fernando P; Martin T; Malamoo L; Welsh J; Banks E
    Med J Aust; 2018 Jun; 209(1):35-41. PubMed ID: 29929455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of prescribing statins according to pharmaceutical benefits scheme criteria.
    Lim SS; Vos T; Peeters A; Liew D; McNeil JJ
    Med J Aust; 2001 Nov; 175(9):459-64. PubMed ID: 11758073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How do the Australian guidelines for lipid-lowering drugs perform in practice? Cardiovascular disease risk in the AusDiab Study, 1999-2000.
    Chen L; Rogers SL; Colagiuri S; Cadilhac DA; Mathew TH; Boyden AN; Peeters A; Magliano DJ; Shaw JE; Zimmet PZ; Tonkin AM;
    Med J Aust; 2008 Sep; 189(6):319-22. PubMed ID: 18803535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of ACC/AHA and ESC Guideline Recommendations Following Trial Evidence for Statin Use in Primary Prevention of Cardiovascular Disease: Results From the Population-Based Rotterdam Study.
    Pavlovic J; Greenland P; Deckers JW; Brugts JJ; Kavousi M; Dhana K; Ikram MA; Hofman A; Stricker BH; Franco OH; Leening MJ
    JAMA Cardiol; 2016 Sep; 1(6):708-13. PubMed ID: 27439175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholesterol-lowering therapy and the Australian Pharmaceutical Benefits Scheme: a population study.
    Adams RJ; Appleton S; Wilson DH; Taylor AW; Chittleborough C; Gill T; Ruffin RE
    Aust Health Rev; 2009 May; 33(2):325-33. PubMed ID: 19563324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Guideline-Based Statin Eligibility, Coronary Artery Calcification, and Cardiovascular Events.
    Pursnani A; Massaro JM; D'Agostino RB; O'Donnell CJ; Hoffmann U
    JAMA; 2015 Jul; 314(2):134-41. PubMed ID: 26172893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of Nontraditional Risk Markers in Individuals Ineligible for Statin Therapy According to the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines.
    Yeboah J; Polonsky TS; Young R; McClelland RL; Delaney JC; Dawood F; Blaha MJ; Miedema MD; Sibley CT; Carr JJ; Burke GL; Goff DC; Psaty BM; Greenland P; Herrington DM
    Circulation; 2015 Sep; 132(10):916-22. PubMed ID: 26224808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
    Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Perkovic V; Hegbrant J; Strippoli GF
    Cochrane Database Syst Rev; 2014 May; (5):CD007784. PubMed ID: 24880031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular disease risk management for Aboriginal and Torres Strait Islander peoples in primary health care settings: findings from the Kanyini Audit.
    Peiris DP; Patel AA; Cass A; Howard MP; Tchan ML; Brady JP; De Vries J; Rickards BA; Yarnold DJ; Hayman NE; Brown AD
    Med J Aust; 2009 Sep; 191(6):304-9. PubMed ID: 19769551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time to improve statin prescription guidelines in low-risk patients?
    Balder JW; de Vries JK; Mulder DJ; Kamphuisen PW
    Eur J Prev Cardiol; 2017 Jul; 24(10):1064-1070. PubMed ID: 28429651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular disease risk assessment for Aboriginal and Torres Strait Islander adults aged under 35 years: a consensus statement.
    Agostino JW; Wong D; Paige E; Wade V; Connell C; Davey ME; Peiris DP; Fitzsimmons D; Burgess CP; Mahoney R; Lonsdale E; Fernando P; Malamoo L; Eades S; Brown A; Jennings G; Lovett RW; Banks E
    Med J Aust; 2020 May; 212(9):422-427. PubMed ID: 32172533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early identification and preventive care for elevated cardiovascular disease risk within a remote Australian Aboriginal primary health care service.
    Burgess CP; Bailie RS; Connors CM; Chenhall RD; McDermott RA; O'Dea K; Gunabarra C; Matthews HL; Esterman AJ
    BMC Health Serv Res; 2011 Jan; 11():24. PubMed ID: 21281520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C-reactive protein: an independent predictor of cardiovascular disease in Aboriginal Australians.
    Wang Z; Hoy WE
    Aust N Z J Public Health; 2010 Jul; 34 Suppl 1():S25-9. PubMed ID: 20618287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes.
    Elam MB; Ginsberg HN; Lovato LC; Corson M; Largay J; Leiter LA; Lopez C; O'Connor PJ; Sweeney ME; Weiss D; Friedewald WT; Buse JB; Gerstein HC; Probstfield J; Grimm R; Ismail-Beigi F; Goff DC; Fleg JL; Rosenberg Y; Byington RP;
    JAMA Cardiol; 2017 Apr; 2(4):370-380. PubMed ID: 28030716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring clinical predictors of cardiovascular disease in a central Australian Aboriginal cohort.
    Luke JN; Brown AD; Brazionis L; O'Dea K; Best JD; McDermott RA; Wang Z; Wang Z; Rowley KG
    Eur J Prev Cardiol; 2013 Apr; 20(2):246-53. PubMed ID: 22345691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemostatic factors in Australian Aboriginal and Torres Strait Islander populations.
    Wang Z; Rowley K; Best J; McDermott R; Taylor M; O'Dea K
    Metabolism; 2007 May; 56(5):629-35. PubMed ID: 17445537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
    Liew D; Park HJ; Ko SK
    Clin Ther; 2009 Oct; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk.
    Soran H; Adam S; Durrington PN
    Atherosclerosis; 2018 Nov; 278():135-142. PubMed ID: 30273874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.